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OBJECTIVE
To date, several methods have been identified for predicting the prognostic subgroups of grade II glio-
mas; however, these methods have some limitations in predicting survival. So, we aimed to determine 
the predictive role of Ki-67 labeling index (LI) on survival.
METHODS
Between 1995 and 2014, patients with grade II gliomas were retrospectively analyzed. All patients re-
ceived radiotherapy (RT).
RESULTS
This study included 78 patients with median 44 (range, 6–137) months follow-up. Patients aged ≥40 years 
had a poorer overall survival (OS) than those aged <40 years (p=0.04). Patients with gross total resection/
subtotal resection had a longer OS than those with biopsy/partial resection (p=0.001). If the disease had 
recurrence or progression during the follow-up period, the patients had a poorer OS (p=0.01). Patients 
with a Ki-67 LI ≥4% had a poorer OS than those with Ki-67 LI < 4% (p=0.001). The extent of resection, 
recurrence, or progression, and Ki-67 ≥4% were the independent prognostic factors for OS.
CONCLUSION
In our opinion, Ki-67 LI is an important prognostic factor for grade II gliomas, but it cannot be used as a 
diagnostic measure alone. It must be used in combination with the other prognostic factors.
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Introduction 
Low-grade gliomas (LGGs) account for 15%–20 % of all 
primary brain tumors. LGGs may eventually undergo 
malignant transformation and progress into high-grade 
gliomas, resulting in high morbidity and mortality. 
LGGs harbor a heterogeneous spectrum of histopatho-
logical subtypes, and therefore, optimal treatment is 
controversial.[1-3] To date, several methods for predict-
ing the prognostic subgroups of LGGs have been iden-
tified. These methods evaluated clinical variables [4,5], 
tumor grading [6], and histopathologic classification.
[6] Tumor grading and histopathologic classification are 
subjective methods since they are based on light micro-
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fractions 5 days a week for a total dose of 50–66 (mean, 
54 Gy) Gy to the tumor (with 1–2 cm margins).
2.3. Histopathology and Ki-67 expression
Two experienced neuropathologist retrospectively re-
defined all tumors based on the 2007 WHO classifica-
tion system for brain tumors.[21] If the neuropatholo-
gist did not agree on the definition of the pathological 
status, a third neuropathologist re-evaluated the tumor 
tissue. Immunohistochemical staining for Ki-67 was 
performed on formalin-fixed, paraffin-embedded tis-
sue sections. Proliferation indexes were reported as the 
percentage of tumor cell nuclei labeled with the Ki-67 
monoclonal antibody in paraffin-embedded specimens. 
For each patient, areas with the highest number of posi-
tively stained tumor nuclei were chosen for reporting.
2.4. Clinical evaluation and follow-up
Following RT, patients were followed up every 3 months 
for 2 years, every 6 months for 3–5 years, and annually 
thereafter.
2.5. Statistical analysis
Statistical analyses were performed using Statistical 
Package for Social Sciences software, v 13.0 (SPSS, 
Chicago, IL, USA). Patient, disease, and treatment 
characteristics were analyzed using descriptive statis-
tics. The median value, mean value, proportion value, 
ranges, and standard deviation values were reported. 
Categorical variables were compared using Pearson’s 
Chi-square test, and continuous variables were com-
pared using independent samples t-test and ANOVA 
test. Overall survival (OS) time was defined as the time 
from diagnosis to the date of the death or last follow-up. 
Progression-free survival (PFS) was defined as the time 
from diagnosis to the date of documented progression 
or recurrence. Survival analyses were performed using 
the Kaplan–Meier method, and subgroups were com-
pared using the two-sided log rank test. Cox propor-
tional hazard regression analysis was used for the esti-
mation of hazard ratios and 95% confidence intervals 
(CIs). Variables with statistical significance (p≤0.05) 
in univariate analysis were included as covariates in 
multivariate analysis. A two-sided p-value of ≤0.05 was 
considered to be statistically significant.
Results
3.1. Patient and tumor characteristics
This study included 78 patients with grade II glial tumors 
with a median follow-up of 44 (range, 6–137 months) 
scopic techniques.[7] Besides, almost all methods for 
predicting the prognostic subgroups of LGGs have some 
limitations in predicting survival. In this regard, there is 
a need to develop new prognostic markers with the aim 
of predicting tumor behavior and prognosis.
Proliferative phases of the cell cycle are composed of 
G1-phase, S-phase, G2-phase, and M-phase. The Ki-67 
monoclonal antibody is detected during all these prolif-
erative phases of the cell cycle, but absent in the resting 
cells (G0-phase).[8] Ki-67 positive cells can be immuno-
chemically imaged, identified, counted, and labeled as a 
percentage of total cells. This relationship is named the 
“labeling index” (LI) or the “proliferation index.” Since 
its discovery in the 1980s, there has been an increas-
ing interest in the role of Ki-67 index as a proliferation 
marker in cancer, and it has been shown to be clinically 
useful in distinguishing the tumor behavior and corre-
lates well with histologic grade, mitotic activity, and oth-
er proliferation markers.[9-18] In this current study, we 
aimed to investigate the possible prognostic relationship 
between Ki-67 LI and the survival outcomes of adult pa-
tients with World Health Organization (WHO) grade II 
glial tumors who were treated with radiotherapy (RT).
Materials and Methods
2.1. Patient population
Between 1995 and 2014, adult patients with grade II gli-
al tumors who had been irradiated at our departments 
were evaluated in this retrospective study. Eligible pa-
tients were required to have histopathologically proven 
grade II glial tumors, be over 16 years of age, and have 
their paraffin-embedded tumor tissue blocks available.
The study was approved by the review boards and con-
ducted according to the ethical principles of the declara-
tion of Helsinki.
2.2. Radiotherapy
Radiotherapy is used in patients with tumors that can-
not be totally removed or in patients with high-risk fea-
tures.[19] High-risk factors were defined by Pignatti and 
colleagues; these factors were identified as age ≥40 years, 
tumor size ≥6 cm, tumor crossing the midline, preopera-
tive neurologic deficit existence, and astrocytoma histol-
ogy subtype. The presence of ≥3 of the above-mentioned 
factors is defined as high risk.[20] Postoperative early RT 
is frequently used in patients with WHO grade II glial 
tumors that cannot be totally resected or in patients who 
are suspected to have high-risk features, whereas de-
layed RT is frequently used in patients with recurrence 
or progression. The patients received RT with 1.8–2 Gy 
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months. Of these patients, 59 had been diagnosed with 
astrocytomas, 15 with oligodendrogliomas, and four 
with oligoastrocytomas. Patients, tumor, and treatment 
characteristics are summarized in Table 1.
3.2. Treatment characteristics
Surgery was the initial treatment approach for all pa-
tients. Gross total resection (GTR) was performed in 
25 patients (32%), subtotal resection (STR) in 35 (45%), 
partial resection (PR) in six (8%), and only biopsy (Bx) 
in 12 (15%). Postoperatively, 51 patients (65%) received 
adjuvant early RT, while 27 patients (35%) received ad-
juvant delayed RT. The median radiation dose was 54 
(range, 50–66) Gy.
3.3. Ki-67 status
Jaros et al. reported that the heterogeneity in Ki-67 LI 
was around 20% astrositomas so that the average values 
of Ki-67 LI represent the proliferative potential of the 
tumor more than the maximal Ki-67 value.[22] Other-
wise, Fisher et al. found that the average Ki-67 value was 
much more associated with survival than the maximal 
value of Ki-67.[23] For this reason, the average Ki-67 
value was used for the analysis. Seventy-two patients 
(92%) were Ki-67 positive (i.e., the percentage of Ki-67 
staining cells was >0). The median Ki-67 LI value was 
1.5% (range, 0–40). The majority of patients (51%) had 
a Ki-67 LI value of ≤2%. Eleven patients (14%) had a Ki-
67 LI value of ≥4% and eight (10%) had a Ki-67 LI value 
of ≥5%. Only one patient had a Ki-67 LI value of ≥10%. 
Survival analyses were performed using the Kaplan–
Meier method at various cutoff points for average Ki-67 
value at 1% intervals between 0% and 10%, and the aver-
age Ki-67 LI value of ≥4% was associated with OS.
3.4. Survival analysis
The median follow-up time was 44 (range, 6–137) 
months. Fifty-six patients (72%) were alive and 20 of 
them had a disease when the survival analysis was per-
formed. The mean OS was 88 (range, 73–102) months. 
The 2-, 5-, and 10-year OS rates were 90%, 70%, and 
Table 1 Patient, tumor, and treatment characteristics




 Range 16-62 
 <40 44 56
 ≥40 34 44
Gender  
 Male 43 55
 Female 35 45
Surgery type  
 Biopsy or parsial resection 18 23
 Subtotal resection 35 45
 Gross total resection 25 32
Histopathology  
 Grade II astrositoma 59 76
 Grade II oligodendroglioma 15 19
 Grade II oligoastrositoma 4 5
Neurologic deficit existence at diagnosis
 No 43 55
 Yes  35 45
Seizures at diagnosis  
 No 44 56
 Yes 34 44
Timing of RT  
 Early  51 65
 Delayed  27 35
Radiation dose (Gy)  
 Median 54 
 Range 50-66 
Chemotherapy  
 No 69 88
 Yes 9 12
Ki-67 index (%)  
 Median  1.5 
 Range 0-40 
 <4 67 86
 ≥4 11 14
Table 2 Univariate cox proportional hazard regression 
analysis related with OS
Variables HR 95% CI P-value
Age   
 <40 years 1  
 ≥40 years 2.34 0.98-5.59 0.056
Extent of removal at diagnosis   
 GTR or STR 1  
 Bx or PR 4.81 1.67-13.87 0.004*
Recurrence or progression   
 No 1  
 Yes 5.56 1.29-10.23 0.02*
Diagnose with biopsy only   
 No 1  
 Yes 4.96 1.67-14.68 0.004*
Ki-67 index   
 <4 % 1  
 ≥4 % 4.49 1.76-11.47 0.002*
Abbreviations: OS, overall survival; GTR, gross total resection; STR, subtotal 
resection; PR, partial resection; Bx, biopsy.
* Statistically significant.
proliferative tumors; therefore, it may be expected that 
patients with higher Ki-67 index might be associated 
with higher radiosensitivity.[23]
In the current study, we aimed to investigate the 
possible prognostic relationship between Ki-67 LI and 
the outcomes of adults with grade II glial tumors who 
were treated with RT. According to our results, age, 
extent of resection, recurrence or progression, and 
average Ki-67 LI value were the significant prognos-
tic factors for OS. The average Ki-67 LI value of ≥4% 
was associated with OS. Patients with a Ki-67 LI value 
of ≥4% had a poorer OS than patients with a Ki-67 LI 
value of <4%. PFS was not affected by Ki-67 LI accord-
ing to our results. This can be explained by the fact that 
PFS may have been more influenced by other prognos-
tic factors, such as variability of surgery and variability 
in the diagnosis of progression.
Despite numerous studies, there are questions 
about the impact of Kİ-67 LI on survival.[7,23,28-32] 
Some authors have reported correlations between Ki-
67 LI and survival.[7,23,29-7] The others did not show 
an association between Ki-67 LI and survival out-
comes.[30,7] These different results can be explained 
by the variety of techniques that evaluate Ki-67 LI, sub-
jectivity of interobserver, and heterogeneity of Ki-67 
level within the specimen.[12] Some studies included 
limited number of patients and histologically hetero-
geneous patient populations. Mckeever et al. reported 
a strong correlation between low Ki-67 LI and longer 
survival in 50 patients with WHO grade II astrocyto-
mas.[29] Fisher et al. showed in their research that an 
average Ki-67 index of >5% was predictive of cause-
specific survival (CSS) and that a maximal Ki-67 index 
of >2% indicated a poorer CSS within the delayed RT 
subgroup.[23] Similarly, Montine et al. revealed that 
patients with a Ki-67 LI ≥3% had a poorer survival 
than patients with a Ki-67 LI of <3%.[13]
Although most of the studies showed a significant 
increase in Ki-67 LI with the increasing grade of astro-
cytomas, Ki-67 LI values overlapped in some studies.
[31] The Ki-67 LI value of glioblastoma can be as low as 
those for LGGs, indicating that the Ki-67 LI value can-
not be used as a diagnostic measure alone [33] and must 
be used in combination with other prognostic factors.
According to our results, the other independent 
prognostic factor that affected OS was recurrence or 
progression of disease. Our current study revealed that 
the avoidance of local recurrence or progression after 
surgery was of comparable relevance to mortality. Lo-
cal recurrence or progression of disease after surgery 
can be included as a risk factor predicting decreased 
40%, respectively. The extent of resection, recurrence, 
or progression and average Ki-67 LI value were the sig-
nificant prognostic factors for OS. A trend of higher 
survival was found in patients aged <40 years. The re-
sults of univariate analysis for OS are summarized in 
Table 2.
Patients with a Ki-67 LI value of ≥4% had a poor-
er OS than patients with a Ki-67 LI value of <4% 
(p=0.001). The mean OS was 96 months for patients 
with a Ki-67 LI value of <4% versus 43 months for the 
patients with a Ki-67 LI value of ≥4% (Fig 1). The mean 
Ki-67 LI value was 1.8% in patients who were alive ver-
sus 4.7% in patients who died of disease (p=0.01).
The mean PFS was 67 (range, 56–77) months for 
all the patients. The 2-, 5-, and 10-year PFS rates were 
85%, 49%, and 12%, respectively. The average Ki-67 LI 
was not associated with PFS. The extent of resection 
was the only independent prognostic factor that af-
fected PFS in survival analysis.
Discussion
Ki-67 LI was presented more than two decades ago as 
a measure of tumor proliferation and because of the 
need for a prognostic marker that might help clini-
cians to direct therapy and predict tumor behavior and 
prognosis [9-18]. Many researchers demonstrated that 
the Ki-67 expression as a cell division marker has been 
associated with radioresistance in some cancers.[24] 
Inhibition of apoptosis could be involved in the com-
plex mechanism of radioresistance with prognostic 
implications.[25-27] Contrary to these opinions, some 
researchers claimed that the proliferative cells have rel-
ative radiosensitivity compared with non-proliferating 
cells.[28] A higher Ki-67 LI theoretically defines more 
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OS for WHO grade II gliomas. There is a need for pro-
spective studies for the clarification of this issue.
WHO classification of central nervous system tu-
mors updated in 2016, which compose genotypic and 
phenotypic parameters. The absence of re-classification 
of tumors according to new version of WHO staging 
and the retrospective feature of the study were the major 
limitations of study.
Conclusion
WHO grade II gliomas are a heterogeneous group of tu-
mors, and there is still significant disagreement between 
clinicians concerning the optimal treatment. Prognostic 
factors are important for the prediction of survival and 
for deciding the most appropriate treatment modality. 
According to our current study, besides the extent of sur-
gery and recurrence or progression, Ki-67 LI ≥4% was an 
independent prognostic factor predicting OS. Although 
Ki-67 LI is a reliable prognostic factor for grade II glial 
tumors, it should not be used as a diagnostic measure 
alone, but in combination with other prognostic factors.
Peer-review: Externally peer-reviewed.
Conflict of Interest: The authors declare that there is no con-
flict of interest.
Funding: This research did not receive any specific grant from 
funding agencies in the public, commercial, or not-for-profit 
sectors.
Acknowledgments: We thank the staff of the Departments 
of Neurosurgery, Neuropathology and Neuroradiology for 
their support.
Authorship contributions: Concept – G.K., E.Y.E.; Design 
– G.K., E.Y.E.; Supervision – G.K., E.Y.E., H.S.E.; Materials – 
G.K., E.Y.E., H.S.E., H.O., M.A., M.K., H.B., E.K.; Data col-
lection &/or processing – G.K., E.Y.E., M.A., M.K., H.B., E.K.; 
Analysis and/or interpretation – G.K., E.Y.E., H.S.E.; Litera-
ture search – G.K., E.Y.E.; Writing – G.K., E.Y.E., H.S.E.; Criti-
cal review – G.K., E.Y.E., H.S.E.
References
1. Shaw E, Arusell R, Scheithauer B, O’Fallon J, O’Neill B, 
Dinapoli R, et al. Prospective randomized trial of low- 
versus high-dose radiation therapy in adults with su-
pratentorial low-grade glioma: initial report of a North 
Central Cancer Treatment Group/Radiation Therapy 
Oncology Group/Eastern Cooperative Oncology 
Group study. J Clin Oncol 2002;20(9):2267–76.
2. Pouratian N, Schiff D. Management of low-grade glio-
ma. Curr Neurol Neurosci Rep 2010;10(3):224–31. 
3. Keles GE, Lamborn KR, Berger MS. Low-grade hemi-
spheric gliomas in adults: a critical review of extent of 
resection as a factor influencing outcome. J Neurosurg 
2001;95(5):735–45.
4. Bauman G, Lote K, Larson D, Stalpers L, Leighton 
C, Fisher B, et al. Pretreatment factors predict overall 
survival for patients with low-grade glioma: a recur-
sive partitioning analysis. Int J Radiat Oncol Biol Phys 
1999;45(4):923–9.
5. Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein 
AS, Fischbach AJ, et al. Recursive partitioning analysis 
of prognostic factors in three Radiation Therapy Oncol-
ogy Group malignant glioma trials. J Natl Cancer Inst 
1993;85(9):704–10.
6. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl 
DK. Improving diagnostic accuracy and interobserver 
concordance in the classification and grading of prima-
ry gliomas. Cancer 1997;79(7):1381–93.
7. Wakimoto H, Aoyagi M, Nakayama T, Nagashima G, 
Yamamoto S, Tamaki M, et al. Prognostic significance 
of Ki-67 labeling indices obtained using MIB-1 mono-
clonal antibody in patients with supratentorial astrocy-
tomas. Cancer 1996;77(2):373–80.
8. Lopez F, Belloc F, Lacombe F, Dumain P, Reiffers J, 
Bernard P, et al. Modalities of synthesis of Ki67 anti-
gen during the stimulation of lymphocytes. Cytometry 
1991;12(1):42–9.
9. Morimura T, Kitz K, Stein H, Budka H. Determination 
of proliferative activities in human brain tumor speci-
mens: a comparison of three methods. J Neurooncol 
1991;10(1):1–11.
10. Ostertag CB, Volk B, Shibata T, Burger P, Kleihues P. 
The monoclonal antibody Ki-67 as a marker for prolif-
erating cells in stereotactic biopsies of brain tumours. 
Acta Neurochir (Wien) 1987;89(3-4):117–21.
11. Zuber P, Hamou MF, de Tribolet N. Identification of 
proliferating cells in human gliomas using the mono-
clonal antibody Ki-67. Neurosurgery 1988;22(2):364–8.
12. Raghavan R, Steart PV, Weller RO. Cell proliferation 
patterns in the diagnosis of astrocytomas, anaplastic as-
trocytomas and glioblastoma multiforme: a Ki-67 study. 
Neuropathol Appl Neurobiol 1990;16(2):123–33.
13. Montine TJ, Vandersteenhoven JJ, Aguzzi A, Boyko OB, 
Dodge RK, Kerns BJ, et al. Prognostic significance of Ki-
67 proliferation index in supratentorial fibrillary astro-
cytic neoplasms. Neurosurgery 1994;34(4):674–8.
14. Jaros E, Perry RH, Adam L, Kelly PJ, Crawford PJ, Kal-
bag RM, et al. Prognostic implications of p53 protein, 
epidermal growth factor receptor, and Ki-67 labelling in 
brain tumours. Br J Cancer 1992;66(2):373–85.
15. Torp SH, Helseth E, Dalen A, Unsgaard G. Relation-
ships between Ki-67 labelling index, amplification of 
the epidermal growth factor receptor gene, and prog-
nosis in human glioblastomas. Acta Neurochir (Wien) 
1992;117(3-4):182–6.
16. Onda K, Davis RL, Shibuya M, Wilson CB, Hoshino T. 
Correlation between the bromodeoxyuridine labeling 
index and the MIB-1 and Ki-67 proliferating cell indices 
in cerebral gliomas. Cancer 1994;74(7):1921–6.
17. Kindblom LG, Ahldén M, Meis-Kindblom JM, Sten-
man G. Immunohistochemical and molecular analysis 
of p53, MDM2, proliferating cell nuclear antigen and 
Ki67 in benign and malignant peripheral nerve sheath 
tumours. Virchows Arch 1995;427(1):19–26.
18. Cunningham JM, Kimmel DW, Scheithauer BW, 
O’Fallon JR, Novotny PJ, Jenkins RB. Analysis of pro-
liferation markers and p53 expression in gliomas of 
astrocytic origin: relationships and prognostic value. J 
Neurosurg 1997;86(1):121–30.
19. Leighton C, Fisher B, Bauman G, Depiero S, Stitt L, 
MacDonald D, et al. Supratentorial low-grade glioma in 
adults: an analysis of prognostic factors and timing of 
radiation. J Clin Oncol 1997;15(4):1294–301.
20. Pignatti F, van den Bent M, Curran D, Debruyne C, Syl-
vester R, Therasse P, et al; European Organization for 
Research and Treatment of Cancer Brain Tumor Coop-
erative Group; European Organization for Research and 
Treatment of Cancer Radiotherapy Cooperative Group. 
Prognostic factors for survival in adult patients with ce-
rebral low-grade glioma. J Clin Oncol 2002;20(8):2076–
84.
21. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burg-
er PC, Jouvet A, et al. The 2007 WHO classification of 
tumours of the central nervous system. Acta Neuro-
pathol 2007;114(2):97–109. 
22. Jaros E, Perry RH, Adam L, Kelly PJ, Crawford PJ, Kal-
bag RM, et al. Prognostic implications of p53 protein, 
epidermal growth factor receptor, and Ki-67 labelling in 
brain tumours. Br J Cancer 1992;66(2):373–85.
23. Fisher BJ, Naumova E, Leighton CC, Naumov GN, 
Kerklviet N, Fortin D, et al. Ki-67: a prognostic fac-
tor for low-grade glioma? Int J Radiat Oncol Biol Phys 
2002;52(4):996–1001.
24. Willett CG, Warland G, Cheek R, Coen J, Efird J, Shellito 
PC, et al. Proliferating cell nuclear antigen and mitotic 
activity in rectal cancer: predictor of response to preop-
erative irradiation. J Clin Oncol 1994;12(4):679–82.
25. Symonds H, Krall L, Remington L, Saenz-Robles M, 
Lowe S, Jacks T, et al. p53-dependent apoptosis sup-
presses tumor growth and progression in vivo. Cell 
1994;78(4):703–11.
26. Thompson CB. Apoptosis in the pathogenesis and treat-
ment of disease. Science 1995;267(5203):1456–62.
27. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-depen-
dent apoptosis modulates the cytotoxicity of anticancer 
agents. Cell 1993;74(6):957–67.
28. Little JB. Differential response of rapidly and slowly 
proliferating human cells to X irradiation. Radiology 
1969;93(2):307–13.
29. McKeever PE, Ross DA, Strawderman MS, Brunberg 
JA, Greenberg HS, Junck L. A comparison of the pre-
dictive power for survival in gliomas provided by MIB-
1, bromodeoxyuridine and proliferating cell nuclear 
antigen with histopathologic and clinical parameters. J 
Neuropathol Exp Neurol 1997;56(7):798–805.
30. Dirven CM, Koudstaal J, Mooij JJ, Molenaar WM. The 
proliferative potential of the pilocytic astrocytoma: the 
relation between MIB-1 labeling and clinical and neuro-
radiological follow-up. J Neurooncol 1998;37(1):9–16.
31. Hilton DA, Love S, Barber R, Ellison D, Sandeman DR. 
Accumulation of p53 and Ki-67 expression do not pre-
dict survival in patients with fibrillary astrocytomas or 
the response of these tumors to radiotherapy. Neurosur-
gery 1998;42(4):724–9.
32. Nakamura M, Konishi N, Tsunoda S, Nakase H, Tsu-
zuki T, Aoki H, et al. Analysis of prognostic and survival 
factors related to treatment of low-grade astrocytomas 
in adults. Oncology 2000;58(2):108–16.
33. Johannessen AL, Torp SH. The clinical value of Ki-67/
MIB-1 labeling index in human astrocytomas. Pathol 
Oncol Res 2006;12(3):143–7. 
